Modified Response Evaluation Criteria in Solid Tumors and European Association for the Study of the Liver Criteria Using Delayed-Phase Imaging at an Early Time Point Predict Survival in Patients with Unresectable Intrahepatic Cholangiocarcinoma following

Modified target mRECIST and EASL criteria that employ delayed-phase contrast enhancement at 3 months after 90Y radioembolization therapy for ICC predicted OS. RECIST did not correlate with survival.